AUGO Earnings

AUGO reported its earnings on 2026-05-06, showcasing a revenue of against an estimate of 386.53M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 2.18 by 0%. The stock experienced a -9.62% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following AUGO's earnings announcement on 2026-05-06, the stock price moved by -9.62% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, AUGO's stock price tends to shift by an average of -0.32% in the 10 days leading up to earnings and -2.88% in the 10 days following, providing insight into potential market.

For , analysts estimate AUGO's annual revenue to reach , while the EPS is projected at . These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between AUGO's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, AUGO's stock price typically moves by -0.32% in the 10 days before its earnings and -2.88% in the 10 days after. For the upcoming earnings, analysts expect an EPS of and revenue of .

The earnings call summary shows strong financial performance with increases in revenue, net income, EBITDA, and cash flow, driven by higher gold production and operational efficiencies. Despite the lack of discussion on operational updates, risks, and returns, the positive financial metrics and strategic outlook indicate a positive sentiment. The absence of negative analyst sentiment in the Q&A further supports this view, suggesting a likely positive stock price movement in the near term.